Munich, Germany

Robert C Phelps

This inventor holds 1 USPTO granted patent. Top assignee: Hexal Gentech Forschungs Gmbh. Active years: 2007.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 37(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Robert C. Phelps

Introduction

Robert C. Phelps is a notable inventor based in Munich, Germany. He has made significant contributions to the field of medical technology, particularly in the area of cancer research. His innovative approach to tumor cell manipulation has the potential to enhance diagnostic and therapeutic strategies.

Latest Patents

One of Robert C. Phelps' key patents is titled "Method for the enriching or depleting tumor cells obtained from a body fluid and kit suitable for this purpose." This invention relates to a method for the enrichment or depletion of tumor cells from a body fluid. The process involves overlaying a cell separation medium of specific density with the body fluid and subjecting it to centrifugation. Additionally, a kit suitable for this method is provided, showcasing the practical application of his invention.

Career Highlights

Robert C. Phelps is associated with Hexal Gentech Forschungs GmbH, where he continues to advance his research and development efforts. His work is instrumental in pushing the boundaries of what is possible in cancer diagnostics and treatment.

Collaborations

Robert collaborates with esteemed colleagues such as Michael Dahm and Carsten Brockmeyer. Their combined expertise fosters an environment of innovation and progress in their respective fields.

Conclusion

Robert C. Phelps exemplifies the spirit of innovation in medical technology through his groundbreaking work on tumor cell manipulation. His contributions are paving the way for advancements in cancer research and treatment methodologies.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…